Results 121 to 130 of about 952,925 (309)

The Lupus Damage Index Revision Program: Results From the Item Generation and Reduction Phases

Arthritis Care &Research, EarlyView.
Objective A data‐driven and expert/patient consensus‐based project to develop a revised Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index (SDI) is under way supported by SLICC, ACR, and the Lupus Foundation of America. Our objective is to report the item generation and reduction phase results
Burak Kundakci, Megan R. W. Barber, Ann E. Clarke, Sindhu R. Johnson, Anselm Mak, Hermine I. Brunner, Murat Inanc, Rosalind Ramsey‐Goldman, Guillermo Ruiz‐Irastorza, Ellen M. Ginzler, John G. Hanly, Alexandra Legge, Cynthia Aranow, Laurent Arnaud, Nathalie Costedoat‐Chalumeau, Dafna D. Gladman, Søren Jacobsen, Michelle Petri, Clovis A. Silva, Évelyne Vinet, Alexandre E. Voskuyl, SDI Revision Literature Review Groups, SDI Revision Delphi Panel, SDI Revision Item Reduction Committee, SDI Revision Clinical Domain Groups, Ian N. Bruce   +25 more
wiley   +1 more source

Peroxisome Proliferator-Activated Receptor alpha (PPAR alpha) down-regulation in cystic fibrosis lymphocytes [PDF]

, 2006
Background: PPARs exhibit anti-inflammatory capacities and are potential modulators of the inflammatory response. We hypothesized that their expression and/or function may be altered in cystic fibrosis (CF), a disorder characterized by an excessive host ...
Wagner, Thomas, Reynders, Veerle, Veerle Reynders, Stefan Loitsch, Joachim Bargon, Reynders Veerle, Thomas Wagner, Steinhauer, Constanze, Bargon Joachim, Steinhilber Dieter, Bargon, Joachim, Loitsch Stefan, Dieter Steinhilber, Constanze Steinhauer, Loitsch, Stefan Marcel, Wagner Thomas, Steinhauer Constanze, Steinhilber, Dieter   +17 more
core   +2 more sources

Determinants of Body Mass Index in Early Systemic Sclerosis: Implications for Nutritional Risk Stratification

Arthritis Care &Research, EarlyView.
Objective Gastrointestinal (GI) involvement can lead to malnutrition in patients with systemic sclerosis (SSc). Body mass index (BMI) remains the most widely used marker to screen nutritional status. We aimed to identify predictors of lower BMI in patients with SSc. Methods Patients with SSc from a prospective US cohort meeting 2013 American College of
Ali Y. Ayla, Meng Zhang, Bingrui Chen, Claudia Pedroza, Brian Skaug, Maureen Mayes, Michael Hughes, Shervin Assassi, Zsuzsanna H. McMahan   +8 more
wiley   +1 more source

Engagement Patterns With an Artificial Intelligence Health Coach for Systemic Sclerosis Self‐Management: A Mixed Methods Study

Arthritis Care &Research, EarlyView.
Objective To evaluate utility of an artificial intelligence (AI) health coach for systemic sclerosis (SSc) self‐management and identify patterns associated with participant engagement. Methods We conducted a mixed methods study in which an AI health coach, powered by a large language model (LLM), was used to support self‐management for SSc.
Nirali Shah, Melanie Morris, Cristina Daraban, Sophia Johnson, Susan L. Murphy   +4 more
wiley   +1 more source

Understanding the Burden of Orofacial Involvement and Patient Treatment Preferences in Systemic Sclerosis: Results From a Large International Survey

Arthritis Care &Research, EarlyView.
Objective Orofacial manifestations are significantly impactful in patients with systemic sclerosis (SSc) yet remain understudied, with no dedicated clinical guidelines to inform their management. Methods An international online survey comprised38 questions addressing orofacial manifestations of SSc, including patients’ confidence in their treating ...
Eleni Deligianni, Lee Shapiro, Deana Gibbs, Zsuzsanna H. McMahan, Michael Hughes   +4 more
wiley   +1 more source

Costs and Benefits of Prenatal Screening For Cystic Fibrosis [PDF]

Newly-developed genetic tests based on restriction fragment length polymorphisms (RFLPs) promise to facilitate the early detection of genetic diseases. Several such tests are now available for the prenatal detection of cystic fibrosis (CF), a common and ...
Alan M. Garber, Joseph P. Fenerty
core  

Clinician and Patient Factors Associated With Long‐Term Glucocorticoid Use in People With Rheumatoid Arthritis Receiving Advanced Therapies

Arthritis Care &Research, EarlyView.
Objective Despite guideline recommendations, long‐term glucocorticoid (GC) use is common in rheumatoid arthritis (RA). We conducted a clinician survey nested within a large registry to identify patient and clinician factors associated with GC use. Methods Clinicians contributing patients to the CorEvitas Rheumatoid Arthritis Registry were surveyed ...
Michael D. George, George Reed, Matthew D. Kearney, Peter F. Cronholm, Kevin Kane, Jeffrey R. Curtis, Dimitrios A. Pappas, Joel M. Kremer   +7 more
wiley   +1 more source

The future of cystic fibrosis care: a global perspective

, 2019
The past six decades have seen remarkable improvements in health outcomes for people with cystic fibrosis, which was once a fatal disease of infants and young children.
Davies, JC, Mathew, JL, Macek, Milan, Macek, M, Raraigh, KS, Gravelle, Anna M, Kashirskaya, Nataliya, Kerem, Eitan, Raraigh, Karen S, Mayer-Hamblett, N, Eichler, I, O'Neill, C, Byrnes, CA, Drevinek, P, Ratjen, F, Rowe, SM, Drevinek, Pavel, Rowe, Steven M, Stephenson, AL, Farrell, PM, Farrell, Philip M, Gutierrez, Hector, Havermans, Trudy, Nasr, Samya Z, Fajac, Isabelle, Tullis, Elizabeth, Stephenson, Anne L, Sivam, S, Goss, CH, Burgel, Pierre-Regis, Byrnes, Catherine A, Castaños, Claudio, Kashirskaya, N, Zampoli, M, Havermans, T, McKone, EF, Goss, Christopher H, Cathcart, F, Castaos, Claudio, McKone, Edward F, Southern, KW, O'Neill, Ciaran, Oates, Gabriela R, Nasr, SZ, Castaños, C, Naehrlich, Lutz, Naehrlich, L, Chotirmall, SH, Pypops, U, Castellani, Carlo, Madge, Susan, Oates, GR, Pypops, Ulrike, Bell, Scott C, Zampoli, Marco, Fajac, I, Sivam, Sheila, Mall, Marcus A, Mathew, Joseph L, Bell, SC, Cathcart, Fiona, Castellani, C, Chotirmall, Sanjay H, Tullis, E, Davies, Jane C, Gravelle, AM, Madge, S, Southern, Kevin W, Kerem, E, Mayer-Hamblett, Nicole, Gutierrez, H, Cosgriff, Rebecca, Cosgriff, R, Ratjen, Felix, Eichler, Irmgard, Mall, MA, Burgel, PR   +76 more
core   +1 more source

The complexities of elexacaftor/tezacaftor/ivacaftor therapeutic drug monitoring in a person with cystic fibrosis and Mycobacterium abscessus pulmonary disease

European Clinical Respiratory Journal
Therapeutic drug monitoring (TDM) of elexacaftor/tezacaftor/ivacaftor (ETI) remains challenging due to a lack of clarity around the parameters that govern ETI plasma concentrations, whilst the use of concomitant CYP3A inducers rifabutin and rifampicin is
Claire Y Mou, Daniel J Henderson, Angela G Matson, Karen M Herd, David W Reid, Timothy Riddles, Ellie Johnson, Brett McWhinney, Rebecca Swenson, Andrew Burke, Ieuan E S Evans   +10 more
doaj   +1 more source

Impact of Six‐Month Monitoring Compared to Three‐Month Monitoring of Laboratories During Methotrexate Therapy

Arthritis Care &Research, EarlyView.
Objective To evaluate whether extending the American College of Rheumatology–recommended monitoring interval for complete blood count and liver function tests in patients receiving methotrexate (MTX) affects timely detection of medication‐related toxicity.
Spencer Simko, Ray Zhang, Sohini Mukherjee, Puneet Bajaj, Bonnie L. Bermas   +4 more
wiley   +1 more source